Is Thorazine (chlorpromazine) still used and what are its indications?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Current Indications and Uses of Thorazine (Chlorpromazine)

Thorazine (chlorpromazine) is still used today, with primary indications including management of psychotic disorders, severe nausea/vomiting, intractable hiccups, acute agitation, and delirium, though it has largely been replaced by newer antipsychotics with better side effect profiles for many indications.

Primary Indications for Chlorpromazine

Psychotic Disorders

  • Schizophrenia and acute psychotic states: FDA-approved for acute and maintenance treatment of schizophrenia 1
    • Dosing typically starts at 25 mg three times daily with gradual increases until symptoms are controlled
    • Maintenance dosage typically ranges from 200-400 mg daily
    • For hospitalized patients with acute schizophrenic or manic states, higher doses may be needed (up to 1000 mg daily)

Non-Psychiatric Indications

  • Nausea and vomiting: 10-25 mg every 4-6 hours as needed 1
  • Intractable hiccups: 25-50 mg three or four times daily 1, 2
  • Pre-surgical apprehension: 25-50 mg, 2-3 hours before surgery 1
  • Acute intermittent porphyria: 25-50 mg three or four times daily 1

Emergency/Acute Settings

  • Chemical restraint for acute agitation: Used in emergency settings for severe agitation when other interventions have failed 2
  • Delirium management: Used for moderate to severe delirium, particularly in palliative care settings 2
    • Dosing typically 12.5-25 mg orally or per rectum, with scheduled dosing every 6-12 hours if needed

Current Status in Clinical Practice

While still available and used, chlorpromazine has largely been supplanted by newer antipsychotics for many indications due to:

  1. Side effect profile: Higher risk of extrapyramidal symptoms (EPS) compared to atypical antipsychotics 3, 4
  2. Cardiac concerns: QT interval prolongation and risk of ventricular arrhythmias 5
  3. Availability of alternatives: Newer atypical antipsychotics generally have better tolerability 3

Special Considerations and Cautions

Side Effects Requiring Monitoring

  • Extrapyramidal symptoms (dystonic reactions)
  • Orthostatic hypotension
  • Sedation and anticholinergic effects
  • QTc interval prolongation
  • Sinus tachycardia and other dysrhythmias 2, 5

Contraindications/Use with Caution

  • Patients with renal or hepatic impairment
  • Cardiovascular disease
  • History of seizures
  • Parkinson's disease or dementia with Lewy bodies 5
  • Patients taking other QT-prolonging medications 2

Specific Populations

  • Elderly patients: Lower dosages recommended due to increased susceptibility to hypotension and neuromuscular reactions 1
  • Pediatric patients: Generally not recommended for children under 6 months except in potentially life-saving situations 1
  • Dementia: Should not be used as first-line management for behavioral and psychological symptoms of dementia 2

Historical Context

Chlorpromazine was one of the first antipsychotic medications and revolutionized the treatment of schizophrenia in the 1950s 6. Despite being an older medication, it remains on the World Health Organization's list of essential drugs 7, indicating its continued importance in global healthcare.

Comparison with Newer Antipsychotics

Studies comparing chlorpromazine to atypical antipsychotics show:

  • Olanzapine may have better clinical response rates 3
  • Risperidone shows similar clinical response but better quality of life scores 3
  • Quetiapine has similar efficacy but significantly fewer extrapyramidal side effects 3

In summary, while newer antipsychotics have largely replaced chlorpromazine as first-line treatments for many conditions, it remains a valuable medication in specific clinical scenarios, particularly in resource-limited settings, for acute management of agitation, and for non-psychiatric indications like intractable hiccups and severe nausea.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia.

The Cochrane database of systematic reviews, 2016

Research

EPS profiles: the atypical antipsychotics are not all the same.

Journal of psychiatric practice, 2007

Guideline

Chapter Title: Management of Psychotic Disorders with Chlorpromazine

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Classics in Chemical Neuroscience: Chlorpromazine.

ACS chemical neuroscience, 2019

Research

Chlorpromazine versus reserpine for schizophrenia.

The Cochrane database of systematic reviews, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.